文献速递心脑血管急症

高出血风险患者PCI术后双联抗血小板治疗的疗程

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
PubMed 文献 · N Engl J Med · 2021-08-28
一句话结论高出血风险患者置入可降解聚合物西罗莫司洗脱支架后1个月即停双抗,净不良临床事件和主要心脑血管事件不劣于继续至少2个月,且大出血或临床相关非大出血更少。

MASTER DAPT研究纳入高出血风险且置入可降解聚合物西罗莫司洗脱支架的患者,支架置入1个月后随机分为立即停用双抗(缩短治疗)或继续至少2个月(标准治疗)。符合方案人群4434例中,净不良临床事件缩短组7.5% vs 标准组7.7%(差异-0.23个百分点,95%CI -1.80至1.33,非劣效P<0.001),主要心脑血管事件6.1% vs 5.9%(差异0.11个百分点,95%CI -1.29至1.51,非劣效P=0.001)。意向治疗人群4579例中,大出血或临床相关非大出血缩短组6.5% vs 标准组9.4%(差异-2.82个百分点,95%CI -4.40至-1.24,优效P<0.001)。

要点

  • 高出血风险患者置入可降解聚合物西罗莫司洗脱支架1个月后,立即停双抗在净不良临床事件上不劣于继续至少2个月(7.5% vs 7.7%,差异-0.23个百分点,95%CI -1.80至1.33)。
  • 主要心脑血管事件(死亡、心梗或卒中)缩短组6.1% vs 标准组5.9%,差异0.11个百分点(95%CI -1.29至1.51),达到非劣效。
  • 大出血或临床相关非大出血缩短组6.5% vs 标准组9.4%,差异-2.82个百分点(95%CI -4.40至-1.24),缩短治疗优效。
  • 研究人群为高出血风险患者,支架为可降解聚合物西罗莫司洗脱支架,停药时机为支架置入后1个月。
  • 主要终点累积发生率评估时间为335天。

适用人群与场景

  • 高出血风险患者,已置入可降解聚合物西罗莫司洗脱冠状动脉支架,支架置入1个月后随机分组。

诊断标准与关键阈值

  • 原文未提及高出血风险的具体定义标准或评分界值。

处置流程与药物剂量

  • 第一步:高出血风险患者置入可降解聚合物西罗莫司洗脱支架。
  • 第二步:支架置入1个月后,随机分为立即停用双联抗血小板治疗(缩短治疗)或继续双抗至少2个月(标准治疗)。
  • 原文未提及双抗的具体药物名称、剂量、给药途径和频次。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:随机对照试验(MASTER DAPT,NCT03023020),由Terumo资助。
  • 符合方案人群4434例:净不良临床事件(全因死亡、心肌梗死、卒中或大出血复合终点)缩短组165例(7.5%)vs 标准组172例(7.7%),差异-0.23个百分点(95%CI -1.80至1.33),非劣效P<0.001。
  • 符合方案人群:主要心脑血管事件(全因死亡、心肌梗死或卒中复合终点)缩短组133例(6.1%)vs 标准组132例(5.9%),差异0.11个百分点(95%CI -1.29至1.51),非劣效P=0.001。
  • 意向治疗人群4579例:大出血或临床相关非大出血缩短组148例(6.5%)vs 标准组211例(9.4%),差异-2.82个百分点(95%CI -4.40至-1.24),优效P<0.001。
  • 累积发生率评估时间为335天。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未明确列出;研究由厂商资助,高出血风险定义未在摘要中详述。

对床旁实践的改变

  • 对于置入可降解聚合物西罗莫司洗脱支架的高出血风险患者,可考虑在支架置入1个月后停用双联抗血小板治疗,而非继续至少2个月,以降低出血风险且不增加净不良临床事件。
  • 适用人群为高出血风险患者,支架类型为可降解聚合物西罗莫司洗脱支架;其他支架类型或非高出血风险人群不适用。
  • 原文未提及高出血风险的具体定义,临床应用中需参照原文完整标准判断。

指南或共识出处

  • MASTER DAPT ClinicalTrials.gov number, NCT03023020(原文提及)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear.

METHODS: One month after they had undergone implantation of a biodegradable-polymer sirolimus-eluting coronary stent, we randomly assigned patients at high bleeding risk to discontinue dual antiplatelet therapy immediately (abbreviated therapy) or to continue it for at least 2 additional months (standard therapy). The three ranked primary outcomes were net adverse clinical events (a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding; cumulative incidences were assessed at 335 days. The first two outcomes were assessed for noninferiority in the per-protocol population, and the third outcome for superiority in the intention-to-treat population.

RESULTS: Among the 4434 patients in the per-protocol population, net adverse clinical events occurred in 165 patients (7.5%) in the abbreviated-therapy group and in 172 (7.7%) in the standard-therapy group (difference, -0.23 percentage points; 95% confidence interval [CI], -1.80 to 1.33; P<0.001 for noninferiority). A total of 133 patients (6.1%) in the abbreviated-therapy group and 132 patients (5.9%) in the standard-therapy group had a major adverse cardiac or cerebral event (difference, 0.11 percentage points; 95% CI, -1.29 to 1.51; P = 0.001 for noninferiority). Among the 4579 patients in the intention-to-treat population, major or clinically relevant nonmajor bleeding occurred in 148 patients (6.5%) in the abbreviated-therapy group and in 211 (9.4%) in the standard-therapy group (difference, -2.82 percentage points; 95% CI, -4.40 to -1.24; P<0.001 for superiority).

CONCLUSIONS: One month of dual antiplatelet therapy was noninferior to the continuation of therapy for at least 2 additional months with regard to the occurrence of net adverse clinical events and major adverse cardiac or cerebral events; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding. (Funded by Terumo; MASTER DAPT ClinicalTrials.gov number, NCT03023020.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Valgimigli M, Frigoli E, Heg D, et al. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021. PMID: 34449185. doi:10.1056/NEJMoa2108749

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。